title: New developments in acne treatment: role of combination adapalene-benzoylperoxide.
abstract: The fixed-dose combination adapalene 0.1%/benzoylperoxide 2.5% (A/BPO) was introduced as an acne vulgaris therapeutic in 2007. It combines anti-inflammatory, keratolytic, comedolytic, and antibacterial properties. Thus, it addresses several pathophysiological factors involved in the pathophysiology of acne. This review highlights the rationale for the use of this fixed-dose combination product, its therapeutic efficacy including effects on adherence and quality of life, its use for different forms of acne, and the side-effect profile. In summary, the fixed-dose combination of A/BPO gel can be regarded as a highly effective and safe formulation. It is not associated with antibiotic resistance. It reduces factors that cause nonadherence and has positive effects on the quality of life of affected patients. The tolerance is good. The initial mild irritation potential can be addressed by adequate counseling. A/BPO can be used for all forms of inflammatory acne, including severe forms, as part of a combination with systemic antibiotics. Finally, it can also be used for the long-term treatment of chronic acne. Thus, it is a very valuable therapeutic option in daily practice, which is reflected by its strong recommendation in the "European S3-guidelines".
authors.affiliation: Clinic for Dermatology, Venereology, and Allergology, University Hospital, Frankfurt/M, Germany.
authors.forename: Su Youn
authors.initials: SY
authors.lastname: Kim
authors.affiliation: Clinic for Dermatology, Venereology, and Allergology, University Hospital, Frankfurt/M, Germany.
authors.forename: Falk R
authors.initials: FR
authors.lastname: Ochsendorf
keywords: acne vulgaris; adapalene; benzoylperoxide; treatment